BeStock  
Stocks › Biotechnology › DNLI

Denali Therapeutics DNLI

US equityMarket cap rank #2440Biotechnology
$18.45 +$0.25 (+1.37%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $18.45 0.00%
Open$17.97
Prev close$18.20
Day range$17.92 – $18.85
Volume2.63M
Market cap$2.96B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$17.78M
Operating profit-$126.75M+7.8% YoY
Net profit$70.13M+155.3% YoY
Diluted EPS$0.37+150.0% YoY
Free cash flow-$125.65M-18.6% YoY
Operating cash flow-$117.44M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$3.6MJun '26$17.8MSep '26

Net profit, last 8 quarters

$-114.8MDec '24$-133.0MMar '25$-124.1MJun '25$-126.9MSep '25$-128.5MDec '25$-128.4MMar '26$-127.6MJun '26$70.1MSep '26

Diluted EPS by quarter

-0.67Dec '24-0.78Mar '25-0.72Jun '25-0.74Sep '25-0.73Dec '25-0.69Mar '26-0.68Jun '260.37Sep '26

Free cash flow by quarter

$-88.8MDec '24$-136.5MMar '25$-79.6MJun '25$-105.9MSep '25$-100.1MDec '25$-133.7MMar '26$-126.6MJun '26$-125.7MSep '26

Annual revenue

$335.7MFY20$48.7MFY21$108.5MFY22$330.5MFY23$0.0FY24$0.0FY25

Profitability & balance sheet

Gross margin98.9%
Operating margin-2,488.1%
Net margin-1,470.5%
Return on equity-33.9%
Return on assets-27.2%
Return on invested capital-35.1%
Current ratio6.21
Liabilities / assets26.2%
Cash & investments$516.20M
Total debt$19.28M
Net cash (debt)$496.92M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $17.78M $3.60M – $0.00 $0.00
Total Operating Revenue $17.78M $3.60M $0.00 $0.00 $0.00
Cost of Revenue $192,000.00 $93,000.00 – – –
Gross Profit $17.59M $3.51M – – –
Operating Expense $144.34M $134.05M $137.36M $555.34M $137.37M
Selling and Admin Expenses $37.49M $36.28M $33.51M $136.56M $39.46M
Research & Development $106.10M $97.02M $103.85M $418.78M $97.91M
Depreciation & Amortization & Depletion $750,000.00 $750,000.00 – – –
-Depreciation & Amortization $750,000.00 $750,000.00 – – –
Operating Profit -$126.75M -$130.54M -$137.36M -$555.34M -$137.37M
Net Non-Operating Interest Income (Expense) $2.88M $2.99M $8.91M $42.90M $8.92M
Non-Operating Interest Income $2.88M $2.99M $8.91M $42.90M $8.92M
Other Income (Expense) $194.00M – – – –
Special Income (Charges) $194.00M – – $0.00 $0.00
-Gain on Sale of Property/Plant/Equipment $194.00M – – – –
Pretax Profit $70.13M -$127.55M -$128.45M -$512.44M -$128.45M
Net Profit $70.13M -$127.55M -$128.45M -$512.54M -$128.55M
Profit from Continuing Operations $70.13M -$127.55M -$128.45M -$512.54M -$128.55M
Net Income to Parent Company $70.13M -$127.55M -$128.45M -$512.54M -$128.55M
Net Income to Common Stockholders $70.13M -$127.55M -$128.45M -$512.54M -$128.55M
Basic EPS $0.37 -$0.68 -$0.69 -$2.97 -$0.73
Diluted EPS $0.37 -$0.68 -$0.69 -$2.97 -$0.73
-General & Admin Expense – $36.28M $33.51M $136.56M $39.46M
-Gain on Sale Of Business – – – $0.00 $0.00
Tax – – – $102,000.00 –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.26B $1.16B $1.27B $1.14B $1.14B
Total Current Assets $591.71M $753.93M $1.02B $900.66M $900.66M
Cash and Cash Equivalents & Short-Term Investments $516.20M $710.47M $987.68M $867.88M $867.88M
-Cash and Cash Equivalents $102.87M $201.53M $387.63M $205.33M $205.33M
-Short Term Investments $413.33M $508.94M $600.06M $662.55M $662.55M
Receivables $18.88M $3.93M – $2.18M $2.18M
-Accounts Receivable $18.88M $3.93M – $2.18M $2.18M
Inventory $26.28M $4.14M – – –
Other Current Assets $30.36M $35.39M $35.07M – –
Total Non-Current Assets $664.33M $404.03M $243.27M $244.20M $244.20M
Net PPE $109.30M $113.42M $117.27M $119.94M $119.94M
-Gross PPE $109.30M $113.42M $117.27M $182.83M $182.83M
Investments and Advances $491.38M $229.53M $63.79M $98.32M $98.32M
-Available for Sale Securities $491.38M – – – –
Goodwill and Other Intangible Assets $34.50M $35.25M $36.00M – –
Other Non-Current Assets $29.15M $25.83M $26.22M $25.94M $25.94M
Total Liabilities $329.65M $322.78M $339.93M $131.09M $131.09M
Total Current Liabilities $95.26M $90.08M $110.16M $98.35M $98.35M
Payables $13.70M $11.81M $40.38M $3.33M $3.33M
-Accounts Payable $13.70M $11.81M $40.38M $3.33M $3.33M
Current Accrued Expenses $33.93M $34.70M $35.58M $32.20M $32.20M
Short-Term Debt and Capital Lease Obligation $10.51M $10.18M $9.86M $9.55M $9.55M
-Current Capital Lease Obligation $10.51M $10.18M $9.86M $9.55M $9.55M
Current Deferred Liabilities $16.42M $19.98M $15.12M $21.10M $21.10M
Total Non-Current Liabilities $234.39M $232.69M $229.77M $32.74M $32.74M
Long Term Debt and Capital Lease Obligation $19.28M $22.03M $24.68M $27.21M $27.21M
-Long Term Capital Lease Obligation $19.28M $22.03M $24.68M $27.21M $27.21M
Other Non-Current Liabilities $215.11M $5.48M $5.51M $5.53M $5.53M
Total Equity $926.39M $835.18M $926.10M $1.01B $1.01B
Stockholders' Equity $926.39M $835.18M $926.10M $1.01B $1.01B
Capital Stock $1.93M $1.92M $1.91M $1.89M $1.89M
-Common Stock $1.93M $1.92M $1.91M $1.89M $1.89M
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $3.17B $3.14B $3.10B $3.06B $3.06B
Retained Earnings -$2.24B -$2.31B -$2.18B -$2.05B -$2.05B
Gains/Losses Not Affecting Retained Earnings -$6.36M -$1.97M -$682,000.00 $682,000.00 $682,000.00
Non-Current Deferred Liabilities – $205.19M $199.58M – –
Prepaid Assets – – – $30.60M $30.60M
-Accumulated Depreciation – – – -$62.90M -$62.90M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$117.44M -$97.00M -$131.20M -$412.60M -$98.54M
Net cash flow from continuing operations -$117.44M -$97.00M -$131.20M -$412.60M -$98.54M
Net Income from Continuing Operations $70.13M -$127.55M -$128.45M -$512.54M -$128.55M
Depreciation & Depletion & Amortization $4.49M $4.48M $3.76M $14.81M $3.78M
Other Non-Cash Items $3.51M $4.22M -$850,000.00 -$4.40M -$1.10M
Change in Working Capital -$23.41M $382,000.00 -$27.50M $149,000.00 $5.02M
-Change in Receivables -$14.96M – – – –
-Change in Inventory -$22.14M – – – –
-Change in Prepaid Assets $5.14M -$322,000.00 -$2.29M -$540,000.00 $1.75M
-Change in Payables and Accrued Expense $15.42M $3.52M -$18.52M -$7.06M $9.32M
-Change in Other Current Assets -$3.32M $396,000.00 -$700,000.00 $772,000.00 -$533,000.00
-Change In Other Working Capital -$3.56M $4.86M -$5.99M $6.97M -$5.52M
Net cash flow from investing $16.19M -$104.08M $94.46M $255.28M $20.77M
Net Cash Flow from Continuing Investing Activities $16.19M -$104.08M $94.46M $255.28M $20.77M
Net PPE Purchase and Sale -$1.01M -$805,000.00 -$2.47M -$9.50M -$1.52M
Net Intangibles Purchase and Sale -$7.20M – – – –
Net Investment Purchase and Sale -$169.60M -$74.47M $96.93M $264.78M $22.29M
Financing Cash Flow $2.59M $14.98M $219.04M $189.22M $192.13M
Net Cash Flow from Continuing Financing Activities $2.59M $14.98M $219.04M $189.22M $192.13M
Net Issuance Payments Of Debt -$22,000.00 -$21,000.00 -$17,000.00 -$8.17M -$16,000.00
Proceeds from Stock Option Exercised $2.61M $15.01M $19.06M $8.46M $3.22M
Net Other Financing Charges $0.00 $0.00 $200.00M -$324,000.00 –
Ending Cash Balance $105.98M $204.64M $390.73M $208.43M $208.43M
Net Change in Cash -$98.66M -$186.10M $182.30M $31.90M $114.36M
Beginning Cash Balance $204.64M $390.73M $208.43M $176.54M $94.07M
Free Cash Flow -$125.65M -$126.61M -$133.67M -$422.10M -$100.06M
-Change in Other Current Liabilities – – – $0.00 –
Net Common Stock Issuance – – – $189.25M $189.25M

Discussion

No comments yet — be the first to weigh in on DNLI.

Sign in to join the discussion.

Scroll to Top